Loading the map…
Private limited company registered in Sale, classed under “Management of real estate on a fee or contract basis” and 1 other activity.
Headline figures
FY to Jun 2025 · Company only
Turnover
For subscribers
Profit after tax
—
Not filed: small-company exemption
Net assets
For subscribers
Cash
For subscribers
Employees
For subscribers
What the numbers say
1 finding from the figures, in plain English
Written by rules from the figures on this page. Not a forecast or a credit opinion.
History
| £ | 2025 |
|---|---|
| Profit after tax | — |
| Turnover | |
| Net assets | |
| Cash | |
| Employees |
Every figure for the year
“—” means we did not find the figure in a source; it is never filled with an estimate.
Balance sheet and ratios
From the filed balance sheets · £
| Balance sheet | 2025 |
|---|---|
| Fixed assets | |
| Current assets | |
| Creditors due within a year | |
| Net current assets | |
| Net assets | |
| Ratios | |
| Current ratioCurrent assets for every £1 owed within a year | |
| Creditors to assetsEverything owed to creditors as a share of fixed plus current assets | |
5 balance-sheet lines and 2 ratios, every year
A ratio appears only for years where every line it needs was filed. Lines are as tagged in the accounts; nothing is added up or estimated.
Questions people ask
›What does The Study Salford do?
Private limited company registered in Sale, classed under “Management of real estate on a fee or contract basis” and 1 other activity.
›How much turnover does The Study Salford make?
Answered in the full report
›Is The Study Salford profitable?
The Study Salford's profit isn't public: small companies may file without a profit and loss account.
›How many people work at The Study Salford?
Answered in the full report
›Where is The Study Salford based?
Its registered office is 98 Haydock Avenue, Sale, M33 4GX, in Sale.
›When was The Study Salford founded?
The Study Salford Ltd was incorporated on 3 June 2024.
›Is The Study Salford still trading?
The register lists The Study Salford Ltd as active.